Nouvelle déclaration d'incident
No de la demande: 2022-6139
Numéro de référence du titulaire d'homologation: CAN-ZZELANCO-CA2022_001688
Nom du titulaire (nom légal complet, aucune abbréviation): Elanco
Adresse: 1919 Minnesota Court, Suite 401
Ville: Mississauga
État: ON
Pays: Canada
Code postal /Zip: L5N 0C9
Incident chez un animal domestique
Pays: CANADA
État: QUEBEC
ARLA No d'homologation 29780 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: K9 Advantix II Large Dog
ARLA No d'homologation 29778 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: K9 advantix II Medium Dog
Oui
Unités: mL
Site: Animal / Usage sur un animal domestique
Inconnu
Professionnel de la santé
Dog / Chien
Chinese Crested
1
Homme
7.8
9.3
kg
Cutanée
Unknown / Inconnu
Unknown / Inconnu
Système
Unknown / Inconnu
Oui
Non
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 27 Apr 2022 the 7.8 year old, 9.3 kg, neutered male, Chinese Crested dog, with a history of heart murmur, was examined and vaccinated with a Distemper, Hepatitis, Parainfluenza, Parvovirus and Leptospirosis and a rabies vaccine. On 6 May 2022, the dog presented generalized pruritus which the owner treated with diphenhydramine. On 7 May 2022, the patient was presented at the emergency clinic because of emesis and diarrhea with blood. The patient was seen by an animal health technician. A bland diet was recommended. On 8 May 2022, the dog presented diarrhea with blood On 9 May 2022, the dog was examined at the clinic. The diarrhea was ongoing without apparent blood in it and the patient was still not eating well and was lethargic. It was treated with sucralfate, maropitant, omeprazole, metronidazole and continued on diphenhydramine. A prescription gastro-intestinal diet was also started. On 12 May 2022, the patients condition had improved and the only ongoing sign was the diarrhea. Probiotics and diphenhydramine were dispensed. On 1 Jun, 1 Jul and 1 Aug 2022, the owner applied the K9 Advantix II large dog dose and the patient reportedly presented pruritus for a few days after each application. On 7 Jun, 7 Jul and 7 Aug 2022, the owner applied Advantage Multi 55 and no signs were observed. On 5 Aug 2022, the owner reported that the dog presented diarrhea, cough and sneezing. The owner indicated that it coincided with the application of K9 Advantix II. On 17 Aug 2022, the owner presented at the desk at the clinic and indicated that she was sure her dog had a reaction to K9 Advantix II and requested a change in medication. On 25 Aug 2022 the patient was examined. The owner indicated it had not entirely recovered since the last application of K9 Advantix II: it was lethargic, had a decreased appetite and appeared to have abdominal pain with associated behavior with the prayers position (collectively coded as abdominal discomfort). The examination did not reveal any new abnormalities and the patient was switched to another preventative medication. At the time of the report, pruritus, decreased appetite and abdominal discomfort were ongoing.
Modérée